Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

LY-23728, 5-HT2B antagonist reported by Lilly

Aug. 16, 1996

Histamine H3 agonist increases slow-wave sleep in rats

Aug. 16, 1996

GW-5823: CCK-A agonist for treatment of obesity

Aug. 16, 1996

Antiarthritic MMP inhibitor described by Chugai

Aug. 16, 1996

HIV integrase inhibitor effective, non-toxic in vitro

Aug. 16, 1996

Preclinical results presented for RCK-11

Aug. 16, 1996

RO-11 demonstrates efficacy in phase III as DVT prevention agent

Aug. 9, 1996

KRH-594: Wakunaga's angiotensin II antagonist

Aug. 9, 1996

Palauolol: A novel antiinflammatory phospholipase A2 inhibitor

Aug. 9, 1996

RD4-2025: Selective HIV-1 reverse transcriptase inhibitor in vitro

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...